Across Medicine

1) Quick framing

• Many agents used in hospitals are multi-indication by design (cardio drugs are used for arrhythmia, ischemia, HTN, HF; psych meds for agitation, nausea, chronic pain; antibiotics for many infections, etc.). I’ll group by system and list common examples + practical notes. 

2) Common hospital drugs with multiple indications (by class)

For each item I list: drug / typical inpatient uses → other uses / pearls.

Cardiovascular

• Beta-blockers (propranolol, metoprolol, carvedilol, bisoprolol)
  → Uses: hypertension, ischemic heart disease/ACS, heart failure (select agents), rate control in atrial fibrillation/flutter, arrhythmias, perioperative cardiac protection.
  → Other: migraine prophylaxis (propranolol), essential tremor, portal hypertension (non-selective β-blockers like propranolol or nadolol for variceal bleed prophylaxis). Pearl: in patients with diabetes β-blockers are indicated for CV protection but can mask adrenergic symptoms of hypoglycemia (tachycardia, tremor). 

• ACE inhibitors / ARBs (lisinopril, enalapril / losartan, valsartan)

• → Uses: HTN, post-MI remodeling, heart failure, proteinuric CKD/diabetic nephropathy. 

• Pearl: avoid or use cautiously with bilateral renal artery stenosis or acute kidney injury. 

• SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin)

• → Uses: type 2 diabetes (glycemic control), heart failure (HFrEF and HFpEF) hospitalization reduction, CKD progression slowing (proteinuric CKD).

• Mineralocorticoid receptor antagonists (MRA) (spironolactone, eplerenone)

• → Uses: HF (mortality benefit in HFrEF), resistant HTN, hyperaldosteronism workup/therapy.

• Diuretics

  • Loop diuretics (furosemide, bumetanide) → volume overload (pulmonary edema, HF), refractory hypercalcemia, acute kidney support for volume removal.

  • Thiazides (chlorthalidone, HCTZ) → HTN, nephrolithiasis prophylaxis (reduce urinary calcium), mild edema.
    Pearl: loops are mainstay for acute decompensated HF; thiazides useful for HTN and stone prevention.

• Calcium-channel blockers (amlodipine, diltiazem, verapamil)

• → Uses: HTN, stable angina, rate control in AF (diltiazem/verapamil), vasospasm (nicardipine for BP control in ICU).

• Nitrates / vasodilators (nitroglycerin, isosorbide dinitrate, hydralazine, nitroprusside)
  → Uses: ischemic chest pain, acute BP control, acute heart failure (venodilators), pulmonary edema.

• Digoxin
  → Uses: rate control in AF (esp. HF with low BP), symptomatic HF in some patients.

Antithrombotic / Hemostasis

• Unfractionated Heparin (UFH) / LMWH (enoxaparin)
  → Uses: prophylaxis and treatment of DVT/PE, anticoagulation in ACS, bridging for procedures, anticoagulation during dialysis/ECMO.

• Direct oral anticoagulants (DOACs) (apixaban, rivaroxaban, dabigatran, edoxaban)

• → Uses: stroke prevention in nonvalvular AF, acute and chronic VTE treatment, VTE prophylaxis in some surgical/medical patients.

• Antiplatelets (aspirin, clopidogrel, ticagrelor)
  → Uses: ACS/PCI, secondary prevention of MI/stroke, sometimes for certain high-risk vascular beds.

Infectious disease / antimicrobial agents

• Doxycycline / macrolides / fluoroquinolones / cephalosporins
  → Uses: broad range of infections (respiratory, skin/soft tissue, atypical pathogens), and some have non-infectious uses (e.g., doxycycline for anti-inflammatory properties in certain dermatologic conditions). (Antibiotic choice is syndrome-specific.)

Analgesia / Pain / Palliative

• Opioids (morphine, hydromorphone, fentanyl, oxycodone)
  → Uses: acute and chronic severe pain, palliative dyspnea relief, cough suppression (some), anesthesia adjuncts.

• NSAIDs (ibuprofen, naproxen, ketorolac)
  → Uses: analgesia, anti-inflammatory, fever; remember renal risks (expanded below).

• Acetaminophen
  → Uses: analgesia, antipyresis — widely used when NSAIDs contraindicated.

Neurology / Psychiatry / Pain modulation

• Antiepileptics used for non-seizure indications

  • Gabapentin / pregabalin → neuropathic pain, fibromyalgia, adjunctive for anxiety, mood stabilization off-label, seizure prophylaxis.

  • Carbamazepine / valproate → bipolar disorder (mood stabilizers), trigeminal neuralgia (carbamazepine) and seizure control.

• SNRIs and TCAs

  • Duloxetine → depression, generalized anxiety and FDA-approved for diabetic peripheral neuropathy and fibromyalgia — commonly used inpatient for neuropathic pain.

  • Amitriptyline / nortriptyline (TCAs) → neuropathic pain, migraine prophylaxis, depression (but caution with anticholinergic effects).

• Antipsychotics

  • Haloperidol → acute agitation/delirium management (IV/IM commonly used in hospitals), psychosis, nausea control (low dose droperidol/haloperidol historically). 

  • Pearl: antipsychotics are used for delirium agitation but evidence for routine prophylactic use is limited and they have QT and extrapyramidal risks.

Endocrine / Metabolic

• Insulins (short/long acting)
  → Uses: glycemic control in diabetes, stress hyperglycemia control, DKA/HHS management (IV insulin).

• Glucocorticoids (prednisone, dexamethasone, methylprednisolone)
  → Uses: anti-inflammatory / immunosuppression (asthma/COPD exacerbation, autoimmune, shock), antiemetic adjunct, cerebral edema, adjunct oncology.

Pulmonary / Critical care

• Nebulized bronchodilators (albuterol) and inhaled steroids
  → Uses: COPD/asthma exacerbations, hyperkalemia (beta-agonists can lower potassium), bronchodilation in ICU settings.

• Vasopressors/inotropes (norepinephrine, epinephrine, dopamine, dobutamine, vasopressin)
  → Uses: septic shock, cardiogenic shock, acute hemodynamic support (each agent has distinct receptors/indications). Pearl: norepinephrine is first-line for septic shock.

Gastrointestinal / Hepatology

• Proton pump inhibitors (omeprazole, pantoprazole)
  → Uses: GERD, peptic ulcer disease, acute GI bleeding, stress ulcer prophylaxis in ICU.

• Octreotide
  → Uses: variceal bleeding control, acromegaly, certain neuroendocrine tumors.

Renal / Electrolyte / Bone

• IV calcium (calcium gluconate/ chloride), calcium binders, phosphate binders
  → Uses: acute electrolyte emergencies, CKD mineral bone disease management.

Hem/Onc:  Immunomodulators

• Corticosteroids, IVIG, interleukin inhibitors used across autoimmune, hematologic, and oncologic indications.

3) Practical caveats / pearls

• “Off-label” is common in hospitals. Many uses above are FDA-approved (e.g., duloxetine for neuropathic pain) and many are guideline-supported or widely practiced off-label.

• Drug selection often depends on comorbidities (e.g., in diabetes pick a beta-blocker carefully because of hypoglycemia masking; in CKD avoid NSAIDs).

• Interactions / combinations matter: the classic “triple-whammy” (ACEi/ARB + diuretic + NSAID) significantly raises AKI risk — important when patients are on multiple chronic meds. 

4) How NSAIDs are toxic to the kidneys — comprehensive, referenced

A. Overview — clinical syndromes caused by NSAIDs

NSAIDs can cause several distinct kidney injuries:

1. Hemodynamically mediated (functional) AKI, due to decreased renal prostaglandin synthesis → afferent arteriole vasoconstriction and reduced GFR. This is the most common acute form.

2. Acute interstitial nephritis (AIN), an immune-mediated hypersensitivity reaction producing AKI (may have fever, rash, eosinophilia).

3. Papillary necrosis / chronic analgesic nephropathy, chronic high-dose NSAID or combined analgesic use → papillary ischemia/necrosis and chronic tubulo-interstitial disease.

4. Electrolyte and acid–base disturbances, hyperkalemia (impaired renin/aldosterone), hyponatremia, fluid retention and worsening heart failure, and sometimes nephrotic-range proteinuria (rare; e.g., NSAID-induced membranous or minimal change disease).

B. Mechanisms, step-by-step

• Inhibition of prostaglandin synthesis (COX-1 and COX-2 blockade)

  • In states where renal perfusion depends on local vasodilatory prostaglandins (prostaglandin E2 and prostacyclin), NSAIDs block COX enzymes → reduced prostaglandin formation → unopposed vasoconstriction of the afferent arteriole → ↓ renal blood flow and ↓ GFR → hemodynamic AKI. High-risk patients include those with volume depletion, CHF, cirrhosis, CKD, advanced age, or concomitant RAAS blockade/diuretics.

• Immune/hypersensitivity (AIN)

  • AIN is typically T-cell–mediated (drug-hapten) with interstitial inflammation; NSAIDs are a well-described cause, onset days to weeks after exposure; sometimes insidious. Biopsy shows interstitial infiltrate and tubulitis.

• Papillary ischemia/necrosis and chronic interstitial nephritis

  • With long-term/high-dose exposure, repeated prostaglandin suppression and other toxic effects cause ischemia of the renal papillae → papillary necrosis and chronic tubular interstitial fibrosis (“analgesic nephropathy”).

• Electrolyte effects

  • NSAIDs can blunt renin and aldosterone → hyperkalemia; can cause fluid retention and worsen edema/HTN; can reduce diuretic response.

• Drug interactions: the “triple-whammy”

  • Combining an ACE inhibitor/ARB + diuretic + NSAID increases AKI risk (diuretic reduces intravascular volume, ACEi/ARB dilate efferent arteriole reducing glomerular pressure, NSAID constricts afferent arteriole), these three mechanisms together can precipitate rapid GFR fall. Avoid this combination when possible.

C. Who’s at highest risk?

• CKD (any stage), elderly, volume-depleted or hypotensive patients, heart failure, cirrhosis with ascites, concomitant RAAS inhibitors or diuretics, ACEi/ARB + diuretic + NSAID combinations, high NSAID doses or prolonged use.

D. Clinical presentation & diagnosis

• Presentation: rise in serum creatinine (AKI), decreased urine output in severe cases, nonspecific symptoms; AIN may add fever, rash, eosinophilia, sterile pyuria. Chronic use → slowly progressive CKD, polyuria, concentration defects, hematuria (papillary necrosis).

• Workup: BMP (creatinine, electrolytes), urinalysis (pyuria, eosinophils possible with AIN), renal ultrasound (exclude obstruction), stop offending NSAID and reassess. If AIN suspected and creatinine not improving, consider nephrology consult and renal biopsy.

E. Management / prevention

1. Immediate: stop the NSAID. Correct hypovolemia if present.

2. Supportive: fluids if volume depleted; monitor urine output and electrolytes.

3. Specific: if AIN suspected and renal function fails to recover after stopping drug, consider corticosteroids (nephrology input; evidence is mixed but often used).

4. Avoid the triple-whammy: review chronic meds — avoid starting NSAIDs in patients on ACEi/ARB + diuretics, or at least counsel and monitor renal function closely.

5) Bottom line / takeaways

• Hospitals use many drugs for multiple, sometimes surprising, indications (cardio drugs for rate control and migraine prevention; antidepressants for neuropathic pain; anticoagulants for both prophylaxis and treatment). I’ve listed the common multi-use agents above; it’s not exhaustive but should cover the medications you’ll most often encounter. 

• NSAID kidney toxicity is common and multi-mechanistic (hemodynamic AKI, AIN, papillary necrosis, electrolyte abnormalities). High-risk patients and the “triple-whammy” deserve special attention — stop NSAIDs promptly if AKI develops.